Alpha-1 antitrypsin - Kamada

Drug Profile

Alpha-1 antitrypsin - Kamada

Alternative Names: A1AT; A1PI; AAT; AAT-IH; AAT-IV; Alpha-1 Antitrypsin; Alpha-1-Antiproteinase; alpha-1-proteinase inhibitor; ALPHA.1-PROTEINASE INHIBITOR HUMAN; Aralast; G1-AAT IV; Glassia; Infinia; Inhaled-AAT; IV AAT; Kamada-API; Prolastin-C

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kamada
  • Developer Kamada; Shire
  • Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Immunomodulators; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Bronchiectasis; Alpha 1-antitrypsin deficiency; Cystic fibrosis; Type 1 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency
  • Phase II/III Graft-versus-host disease; Type 1 diabetes mellitus
  • Phase II Bronchiectasis; Cystic fibrosis; Lung transplant rejection

Most Recent Events

  • 01 Aug 2017 Kamada completes enrolment in a phase II trial for Lung transplant rejection (Adjunctive treatment, Prevention) in Israel (IV)
  • 01 Aug 2017 Kamada plans a phase II/III trial for Graft-versus host disease in USA and European Union in 2018
  • 22 Jun 2017 Kamada withdraws the MAA with the EMA for inhaled Alpha-1 antitrypsin therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top